We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
By describing the essentials of five trail-blazing programs that treat a wide range of stress-related illnesses (heart disease, depression, diabetes, functional neurological disorders, bodily distress disorders, and comorbid depression and diabetes or heart disease), this chapter distills the features common across these treatment approaches. They provide a guide for what we can expect if we want to slow or stop the course of a stress-related illness.
Functional somatic disorder (FSD) is a unifying diagnosis that includes functional somatic syndromes such as irritable bowel, chronic widespread pain (CWP) and chronic fatigue. Several psychological factors are associated with FSD. However, longitudinal population-based studies elucidating the causal relationship are scarce.
Aims
To explore if neuroticism, perceived stress, adverse life events (ALEs) and self-efficacy can predict the development of FSD over a 5-year period.
Method
A total of 4288 individuals who participated in the DanFunD baseline and 5-year follow-up investigations were included. FSD was established at both baseline and follow-up, with symptom questionnaires and diagnostic interviews. Neuroticism was measured with the short-form NEO Personality Inventory, perceived stress with the Cohen's Perceived Stress Scale, ALEs with the Danish version of the Cumulative Lifetime Adversity Measure and self-efficacy with the General Self-Efficacy Scale. Associations were investigated with multiple logistic regression models.
Results
Perceived stress predicted incident FSD, irritable bowel, CWP and chronic fatigue (odds ratios: 1.04–1.17). Neuroticism predicted incident FSD and chronic fatigue (odds ratios: 1.03–1.16). ALEs predicted incident FSD, CWP and chronic fatigue (odds ratios: 1.06–1.18). An increase in perceived stress from baseline to follow-up was associated with incident FSD, irritable bowel, CWP and chronic fatigue (odds ratios: 1.05–1.22). Contrary, an increase in self-efficacy seemed to be a protective factor (odds ratios: 0.89–0.99).
Conclusions
High neuroticism, high perceived stress and a high number of ALEs are risk factors for the development of FSD. Particularly perceived stress seems to be an important contributor to the onset of FSD.
Somatic symptom disorders (SSD) and functional somatic syndromes (FSS) are often regarded as similar diagnostic constructs; however, whether they exhibit similar clinical outcomes, medical costs, and medication usage patterns has not been examined in nationwide data. Therefore, this study focused on analyzing SSD and four types of FSS (fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, functional dyspepsia).
Methods
This population-based matched cohort study utilized Taiwan's National Health Insurance (NHI) claims database to investigate the impact of SSD/FSS. The study included 2 615 477 newly diagnosed patients with SSD/FSS and matched comparisons from the NHI beneficiary registry. Healthcare utilization, mortality, medical expenditure, and medication usage were assessed as outcome measures. Statistical analysis involved Cox regression models for hazard ratios, generalized linear models for comparing differences, and adjustment for covariates.
Results
All SSD/FSS showed significantly higher adjusted hazard ratios for psychiatric hospitalization and all-cause hospitalization compared to the control group. All SSD/FSS exhibited significantly higher adjusted hazard ratios for suicide, and SSD was particularly high. All-cause mortality was significantly higher in all SSD/FSS. Medical costs were significantly higher for all SSD/FSS compared to controls. The usage duration of all psychiatric medications and analgesics was significantly higher in SSD/FSS compared to the control group.
Conclusion
All SSD/FSS shared similar clinical outcomes and medical costs. The high hazard ratio for suicide in SSD deserves clinical attention.
Psychological treatment for functional somatic syndromes (FSS) has been found moderately effective. Information on how much treatment is needed to obtain improvement is sparse. We assessed the efficacy of a brief and extended version of group-based Acceptance and Commitment Therapy (ACT) v. enhanced care (EC) for patients with multiple FSS operationalised as Bodily Distress Syndrome multi-organ type.
Methods
In a randomised controlled three-armed trial, consecutively referred patients aged 20–50 with multiple FSS were randomly assigned to either (1) EC; (2) Brief ACT: EC plus 1-day workshop and one individual consultation; or (3) Extended ACT: EC plus nine 3-h group-based sessions. Primary outcome was patient-rated overall health improvement on the five-point clinical global improvement scale 14 months after randomisation. A proportional odds model was used for the analyses.
Results
A total of 180 patients were randomised; 60 to EC, 61 to Brief ACT, and 59 to Extended ACT. Improvement on the primary outcome after Extended ACT was significantly greater than after EC with an unadjusted OR of 2.9 [95% CI (1.4–6.2), p = 0.006]. No significant differences were found between Brief ACT and EC. Of the 18 secondary outcomes, the only significant difference found was for physical functioning in the comparison of Extended ACT with EC.
Conclusions
Patients rated their overall health status as more improved after Extensive ACT than after EC; however, clinically relevant secondary outcome measures did not support this finding. Discrepancies between primary and secondary outcomes in this trial are discussed.
This chapter provides an overview of the current state of evidence regarding treatment of medically unexplained symptoms, somatisation and the functional somatic syndromes. Both primary and secondary care studies have been performed to assess the efficacy of psychological interventions, most commonly cognitive behaviour therapy administered by a mental health professional, or antidepressants, prescribed by the patient's usual doctor. Thirteen trials evaluated cognitive behaviour therapy, five evaluated antidepressants, four the effect of a consultation letter to the general practitioner (GP) and three the training of GPs. The chapter reviews psychological treatments and the use of antidepressants. It uses three systematic reviews to provide an overview of the evidence of efficacy of interventions for functional somatic symptoms. The evidence is stronger for some pharmacological treatments than for psychological treatments partly because of the universal use of placebo tablets and the lack of an attention-placebo in psychological treatment trials.
This chapter considers three groups, medically unexplained symptoms, somatoform disorders, and functional somatic syndromes. Describing the nature of these groups, it talks about their prevalence in cross-sectional studies in primary, secondary care and population-based studies. Medically unexplained symptoms are very common both in the general population and in primary and secondary care, but at least in the first two settings most are transient. Systematic reviews of the prevalence of irritable bowel syndrome in population-based samples have indicated that the prevalence varies considerably with the definition of the syndrome. Functional somatic syndromes are also common but only some patients with these syndromes also have numerous somatic symptoms. There is little doubt that somatoform disorders, or bodily distress syndromes, are an important and challenging group of conditions that are expensive in terms of healthcare use and time missed from work.
The mechanisms underlying the co-occurrence of the functional somatic syndromes are largely unknown. No empirical study has explicitly examined how genetic and environmental factors influence the co-morbidity of these syndromes. We aimed to examine how the co-morbidity of functional somatic syndromes is influenced by genetic and environmental factors that are in common to the syndromes.
Method
A total of 31318 twins in the Swedish Twin Registry aged 41–64 years underwent screening interviews via a computer-assisted telephone system from 1998 to 2002. Four functional somatic syndromes (chronic widespread pain, chronic fatigue, irritable bowel syndrome, and recurrent headache) and two psychiatric disorders (major depression and generalized anxiety disorder) were assessed using structured questions based on standard criteria for each illness in a blinded manner.
Results
Multivariate twin analyses revealed that a common pathway model with two latent traits that were shared by the six illnesses fit best to the women's data. One of the two latent traits loaded heavily on the psychiatric disorders, whereas the other trait loaded on all four of the functional somatic syndromes, particularly chronic widespread pain, but not on the psychiatric disorders. All illnesses except the psychiatric disorders were also affected by genetic influences that were specific to each.
Conclusions
The co-occurrence of functional somatic syndromes in women can be best explained by affective and sensory components in common to all these syndromes, as well as by unique influences specific to each of them. The findings clearly suggest a complex view of the multifactorial pathogenesis of these illnesses.
The functional somatic syndromes (FSS) refer to a number of related syndromes that have been characterized by the reporting of somatic symptoms and resultant disability rather than on the evidence of underlying conventional disease processes. Chronic fatigue syndrome, irritable bowel syndrome and fibromyalgia have been more extensively researched than most other FSS which has led to specific pathophysiological mechanisms being advanced for each. There is limited data on the predisposing and precipitating factors in FSS. A history of childhood abuse is more common in those who suffer from irritable bowel syndrome, chronic fatigue syndrome, and fibromyalgia. Cognitive behavioural therapy and exercise therapy appear to lead to therapeutic change by tackling biological and psychosocial factors, whilst centrally acting drugs such as antidepressants can sometimes be helpful. For many of the less well recognized FSS, operationalized diagnostic criteria are lacking, as are high quality treatment trials.
This chapter outlines various psychotherapeutic techniques that have proved to be effective in the treatment of functional somatic syndromes. The role of psychotherapy in the treatment of bodily diseases depends on the extent to which psychological factors play a role in their etiology and course. Cognitive-behavioral therapy (CBT) is considered to be the treatment of choice for a wide range of functional somatic syndromes. Deconstructing the patient's perception of his or her condition and developing a new, shared formulation of the illness is crucial to the success of cognitive-behavioral therapy. Chronic fatigue syndrome is used to demonstrate this technique. The treatment of functional somatic syndromes requires the coordinated efforts of a variety of health professionals to minimize duplication of medical investigations. Anxiety states and depressive episodes in particular frequently require immediate relief in order to allow and encourage the patient to participate in the psychotherapeutic relationship.
This chapter discusses the distribution of the literature publications among the nine functional somatic syndromes indicating that only the disabilities claimed by patients with fibromyalgia and chronic fatigue syndrome (CFS) have been the object of sustained scientific attention. In both CFS and fibromyalgia, the common disabling symptoms consist of cognitive deficits and exercise intolerance. The psychiatric evaluation serves the purpose of identifying and treating disabling mental disorders that are allowed to coexist with CFS. Neuropsychological disturbances, particularly poor memory and difficulty with tasks that require sustained attention and concentration, are commonly reported among the disabling symptoms of patients with CFS and fibromyalgia. An important task for the disability evaluator is to determine whether the allegedly disabling chronic pain symptom belongs to a functional somatic syndrome or is the defining complaint of a discrete chronic pain syndrome.
This chapter describes current knowledge about two drug treatments of depression, anxiety, pain and sleep disorders as these psychiatric syndromes often accompany the functional somatic syndromes. Monoamine oxidase inhibitors (MAOIs) came from the antitubercular drug iproniazid that appeared to alleviate depression in patients with tuberculosis. Psychotic depression, i.e., major depression with delusions and/or hallucinations, responds better to a combination of an antidepressant and an antipsychotic than to either drug given separately. Short-lived anxiety suggests use of benzodiazepines with shorter half-lives, while with the longer lasting anxiety, benzodiazepines with longer half-lives could be used. Antidepressants such as tricyclic agents, selective serotonin reuptake inhibitors and trazodone have shown usefulness for patients with generalized anxiety disorder. All the benzodiazepines used for anxiety also serve as hypnotics. Carbamazepine, an anticonvulsant agent, has shown efficacy especially for neurogenic pain, at doses of 200-1200 mg/day, in divided doses.
Functional somatic syndromes are physical illnesses without an organic disease explanation and devoid of demonstrable structural lesion or established biochemical change. The degree to which these syndromes have been characterized as unique entities is variable. In 1989 two Harvard Medical School researchers J.I.Hudson and H.G.Pope Jr. published an analysis of the association between fibromyalgia and psychopathology. They formulated three explanatory hypotheses: fibromyalgia is the cause of psychopathology; fibromyalgia is the effect of psychopathology; fibromyalgia and psychopathology are the result of a common underlying morbid process. For fibromyalgia, Robert Kellner suggested that physical disease, psychopathology and low serotonin concentration cause abnormalities in non-rapid eye movement sleep. Kellner also addressed the tendency for clustering of functional somatic syndromes, a prominent feature of the work of Hudson & Pope and D.Stewart. Kellner's work has been continued and expanded in the latest contribution to the evolution of ideas regarding the etiology of these syndromes.
This chapter describes major research directions in the study of each of the nine functional somatic syndromes and highlights the overlapping dimensions. The fact that a substantial proportion of chronic fatigue syndrome (CFS) patients have concurrent symptoms sufficient for a diagnosis of major depression has prompted the investigation of the serotonin function with the new method of d-fenfluramine challenge. A genetic factor responsible for the family aggregation of fibromyalgia has been demonstrated among patients attending the rheumatology clinic of the University Hospital, Beer Sheva, Israel. The presence of chronic pelvic pain in patients with irritable bowel was associated with a significantly higher likelihood of childhood sexual abuse, panic disorder and a lifetime history of somatization disorder. A prominent biological abnormality of patients with premenstrual syndrome is serotonergic deficiency. There is substantial evidence that mast cell activation plays an important role in the production of abnormalities associated with interstitial cystitis (IC).
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.